Table 18Key Question 3 – therapy duration: Clopidogrel vs. placebo: 30-days vs. 12 months (PCI-CURE)

Domains pertaining to strength of evidenceMagnitude of effectStrength of evidence
Number of studies; number of subjectsRisk of bias (design/quality)ConsistencyDirectnessPrecisionRR (95% confidence interval)High, moderate, low, insufficient
All-cause mortality
1/N=2658Low (RCT/Good)NRInsufficient
Cardiovascular mortality
1/N=2658Low (RCT/Good)ConsistentIndirectImprecise1.07 (0.65 to 1.75)Low
Revascularization
1/N=2658Low (RCT/Good)ConsistentIndirectImprecise0.82 (0.68 to 1.00)Moderate
Major bleeding
1/N=2658Low (RCT/Good)ConsistentIndirectImprecise1.12 (0.70 to 1.78)Low
Withdrawal due to adverse events
1/N=2658Low (RCT/Good)NRInsufficient
a

Calculated by OR EPC using StatsDirect.

From: Appendix F, Strength of evidence

Cover of Drug Class Review: Newer Antiplatelet Agents
Drug Class Review: Newer Antiplatelet Agents: Final Update 2 Report [Internet].
Ketchum K, Peterson K, Thakurta S, et al.
Portland (OR): Oregon Health & Science University; 2011 Jun.
Copyright © 2011 by Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.